Today’s article highlights a dozen emerging pharmaceutical companies that could potentially have a big year – and identifies the multiple catalysts that 2017 holds for each of them – from financials releases to key clinical trial milestones to potential acquisition. To find out what these 12 emerging pharmaceutical companies are, what the analyst sentiment on them is, and what their respective catalysts this year are (and when they are set to occur), CLICK HERE.